Home

Driving the Data-Rich Future of OSDs
Data-rich, data-led, data-driven — these terms increasingly define modern oral solid dose development. In this roundtable, industry leaders discuss what it will take to navigate this next phase of OSD innovation. read more
Peptide-to-Small-Molecule Translation
Recent advances are turning what was once a trial-and-error exercise into a disciplined and reproducible design workflow. read more
Particle Size Meets Chemistry
As material complexity and regulatory expectations grow, LD-PCRS correlative characterization will support robust formulation design, process control, and risk-based decision-making. read more
Handling Machinability Challenges with Hard Shell Capsules
Machinability issues linked to capsule-related factors can disrupt production, increase waste and jeopardize delivery timelines. read more

FDA Hits Cingulate with CRL for ADHD Tablet, Citing CMC Issues
June 05, 2026
The letter did not raise any concerns regarding the clinical safety or efficacy of CTx-1301. read more
Madrigal Oral MASH Drug Gets UK Approval
June 04, 2026
Rezdiffra is the first approved oral treatment for metabolic dysfunction-associated steatohepatitis in both the U.S. and UK. read more
Servier Bets $2.65B on Edgewise Muscular Dystrophy Biz
June 01, 2026
The deal centers around Edgewise’s sevasemten, an investigative orally administered first-in-class fast skeletal myosin inhibitor. read more